Skip to content
Sexuality – Lifestyle
Author:
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
April 7, 2026
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
March 26, 2026
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
March 18, 2026
←
Previous Page
1
2